Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells

Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET

(2022) Arpita S. Pal et al.   CANCER RESEARCH

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

(2022) D. Ross Camidge et al.   Clinical Lung Cancer

Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

(2022) Alissa J. Cooper et al.   Nature Reviews Clinical Oncology

Age-related elevation of HGF is driven by the reduction of fibroblast size in a YAP/TAZ/CCN2 axis-dependent manner

(2021) Yaping Xiang et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib

(2021) Paul Dent et al.   BIOCHEMICAL PHARMACOLOGY

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial

(2021) Tithi Biswas et al.   CLINICAL CANCER RESEARCH

Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling

(2020) Paul Dent et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]

(2020) Paul Dent et al.   CELLULAR SIGNALLING

Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer

(2020) Laurence Booth et al.   BIOCHEMICAL PHARMACOLOGY

YAP orchestrates heterotypic endothelial cell communication via HGF/c-MET signaling in liver tumorigenesis

(2020) Stefan Thomann et al.   CANCER RESEARCH

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

(2019) Helen Adderley et al.   EBioMedicine

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells

(2019) Paul Dent et al.   ONCOGENE

Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model

(2018) Ping-Chih Hsu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Neratinib augments the lethality of [regorafenib + sildenafil]

(2018) Laurence Booth et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma

(2018) Abdalla D. Mohamed et al.   Scientific Reports

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells

(2018) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

(2017) Laurence Booth et al.   Oncotarget

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

(2017) Laurence Booth et al.   Oncotarget

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration

(2014) J. W. Haskins et al.   Science Signaling

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

(2014) W. Zhang et al.   Science Signaling

EGFR Mutations in Lung Adenocarcinomas

(2008) Allan R. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS